公开(公告)号：US20150191464A1

公开(公告)日：2015-07-09

申请号：US14588470

申请日：2015-01-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph B. Santella ,  Sreekantha Ratna Kumar ,  John V. Duncia ,  Daniel S. Gardner ,  Venkatram Reddy Paidi ,  Satheesh Kesavan Nair ,  John Hynes ,  Hong Wu ,  Natesan Murugesan ,  Kandhasamy Sarkunam ,  Piramanayagam Arunachalam

IPC: C07D471/04 ,  C07D519/00 ,  C07D401/14 ,  C07F9/6561 ,  C07D401/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D487/04 ,  C07D519/00 ,  C07F9/65616

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Abstract translation: 公开了式（I）的化合物或其盐，其中：HET是选自吡唑基，吲哚基，吡咯并[2,3-b]吡啶基，吡咯并[2,3-d]嘧啶基，吡唑并[3,4- b]吡啶基，吡唑并[3,4-d]嘧啶基，2,3-二氢-1H-吡咯并[2,3-b]吡啶基，咪唑并[4,5-b]吡啶基和嘌呤基，其中所述杂芳基被取代 与Ra和Rb; 并且R1和R2在本文中定义。 还公开了使用这样的化合物作为IRAK4的调节剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓炎症和自身免疫性疾病。

公开(公告)号：US09169252B2

公开(公告)日：2015-10-27

申请号：US14588470

申请日：2015-01-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph B. Santella ,  Sreekantha Ratna Kumar ,  John V. Duncia ,  Daniel S. Gardner ,  Venkatram Reddy Paidi ,  Satheesh Kesavan Nair ,  John Hynes ,  Hong Wu ,  Natesan Murugesan ,  Kandhasamy Sarkunam ,  Piramanayagam Arunachalam

IPC: C07D213/02 ,  C07D519/00 ,  C07D401/14 ,  C07D471/04 ,  C07D401/04 ,  C07D487/04 ,  C07F9/6561

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D487/04 ,  C07D519/00 ,  C07F9/65616

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Abstract translation: 公开了式（I）的化合物或其盐，其中：HET是选自吡唑基，吲哚基，吡咯并[2,3-b]吡啶基，吡咯并[2,3-d]嘧啶基，吡唑并[3,4- b]吡啶基，吡唑并[3,4-d]嘧啶基，2,3-二氢-1H-吡咯并[2,3-b]吡啶基，咪唑并[4,5-b]吡啶基和嘌呤基，其中所述杂芳基被取代 与Ra和Rb; 并且R1和R2在本文中定义。 还公开了使用这样的化合物作为IRAK4的调节剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓炎症和自身免疫性疾病。